MTOR and breast cancer: In addition to the PI3K/Akt/mTOR, MAPK, and NF-κB pathways, other oncogenic signaling pathways like Hippo, Notch1, and Wnt/β-catenin also play roles in the HER2-targeted therapy resistance of BC [159].